Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jun 6:1:9.
doi: 10.1186/1745-6673-1-9.

The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations

Affiliations

The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations

Semaan G Kosseifi et al. J Occup Med Toxicol. .

Abstract

4,4'-Diaminodiphenylsulphone (Dapsone) is widely used for a variety of infectious, immune and hypersensitivity disorders, with indications ranging from Hansen's disease, inflammatory disease and insect bites, all of which may be seen as manifestations in certain occupational diseases. However, the use of dapsone may be associated with a plethora of adverse effects, some of which may involve the pulmonary parenchyma. Methemoglobinemia with resultant cyanosis, bone marrow aplasia and/or hemolytic anemia, peripheral neuropathy and the potentially fatal dapsone hypersensitivity syndrome (DHS), the focus of this review, may all occur individually or in combination. DHS typically presents with a triad of fever, skin eruption, and internal organ (lung, liver, neurological and other systems) involvement, occurring several weeks to as late as 6 months after the initial administration of the drug. In this sense, it may resemble a DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms). DHS must be promptly identified, as untreated, the disorder could be fatal. Moreover, the pulmonary/systemic manifestations may be mistaken for other disorders. Eosinophilic infiltrates, pneumonitis, pleural effusions and interstitial lung disease may be seen. This syndrome is best approached with the immediate discontinuation of the offending drug and prompt administration of oral or intravenous glucocorticoids. An immunological-inflammatory basis of the syndrome can be envisaged, based on the pathological picture and excellent response to antiinflammatory therapy. Since dapsone is used for various indications, physicians from all specialties may encounter DHS and need to familiarize themselves with the salient features about the syndrome and its management.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Computed chest tomography of the patient described in this report, showing bilateral interstitial infiltrates (yellow arrow) and pleural effusions (red arrow). Image taken at a mid-thoracic level.

References

    1. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45:420–434. doi: 10.1067/mjd.2001.114733. - DOI - PubMed
    1. Singletary EM, Rochman AS, Bodmer JC, Holstege CP. Envenomations 1. Med Clin North Am. 2005;89:1195–1224. doi: 10.1016/j.mcna.2005.07.001. - DOI - PubMed
    1. Leslie KS, Gaffney K, Ross CN, Ridley S, Barker TH, Garioch JJ. A near fatal case of the dapsone hypersensitivity syndrome in a patient with urticarial vasculitis. Clin Exp Dermatol. 2003;28:496–498. doi: 10.1046/j.1365-2230.2003.01336.x. - DOI - PubMed
    1. Pavithran K, Bindu V. Dapsone syndrome: hepatitis-B infection a risk factor for its development? Int J Lepr Other Mycobact Dis. 1999;67:171–172. - PubMed
    1. Knowles SR, Shapiro LE, Shear NH. Reactive metabolites and adverse drug reactions: clinical considerations. Clin Rev Allergy Immunol. 2003;24:229–238. doi: 10.1385/CRIAI:24:3:229. - DOI - PubMed

LinkOut - more resources